Q4 2024 Management View CEO Richard Miller detailed the progress of soquelitinib, emphasizing its potential as a first-in-class oral therapy for immune diseases and cancers. He highlighted the 39% ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Speakers from the Muscular Dystrophy Association (MDA) highlighted 75 years of progress in understanding and treating ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a subgroup of breast cancer patients, but not the overall study population.

This Perspective outlines evidence on existing platform trials in mental health and discusses key challenges and strategies to overcome barriers in order to maximize the potential of platform trials.

In this atmosphere, the trial for the death of Diego Armando Maradona ... a psychoanalyst dedicated to addiction treatment, clinical physician Pedro Di Spagna, the coordinator of the contracted ...

ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

Seven members of the medical team that treated Diego Maradona before his death will today go on trial for homicide in ... tended to the former athlete and clinical physician Pedro Pablo Di Spagna.

A jury on Monday sided with Disney in a copyright trial involving “Moana,” clearing the company of an infringement suit brought by a screenwriter. The plaintiff, Buck Woodall, filed suit in ...

The STARI trial (NCT06832306), a Phase 2 feasibility study ... to investigational use. Used exclusively for clinical investigations.